Norton Rose Fulbright has advised a consortium formed by domestic and international financial institutions on the PLN 800 million (EUR 177 million) unsecured financing granted to Zaklady Farmaceutyczne Polpharma S.A. Clifford Chance advised Polpharma on the matter.
The syndicate of lenders included BNP Paribas Bank Polska S.A. as the facility agent and Powszechna Kasa Oszczednosci Bank Polski S.A., Santander Bank Polska S.A., and EBRD as lenders.
According to NRF, Polpharma S.A. is the largest Polish manufacturer of pharmaceuticals. The firm actively operates in the markets of Central and Eastern Europe, the Caucasus, and Central Asia. It also informed that the funds will be used for the purpose of refinancing, financing of capex and working capital requirements, and the financing of R&D projects and green economy transition investments.
NRF’s team included Partners Grzegorz Dyczkowski and James Dunnett, Counsel Marta Kawecka, and Associate Karolina Majcher.
Clifford Chance's team included Partner Andrzej Stosio, Senior Associate Anna Miernik, and Associate Natalia Karasiewicz.
